EGFR T790M

genetic variant
Thing missense_mutation Q25100112
Press Enter · cited answer in seconds

EGFR T790M

Summary

EGFR T790M is a missense mutation[1]. It draws 10 Wikipedia views per month (missense_mutation category, ranking #1 of 1).[2]

Key Facts

  • EGFR T790M's instance of is recorded as missense mutation[3].
  • EGFR T790M's genomic start is recorded as 55249071[4].
  • EGFR T790M's genomic end is recorded as 55249071[5].
  • EGFR T790M's chromosome is recorded as human chromosome 7[6].
  • EGFR T790M's Google Knowledge Graph ID is recorded as /g/11bwqm1h47[7].
  • EGFR T790M's CIViC variant ID is recorded as 34[8].
  • EGFR T790M's HGVS nomenclature is recorded as ENST00000275493.2:c.2369C>T[9].
  • EGFR T790M's HGVS nomenclature is recorded as NM_005228.4:c.2369C>T[10].
  • EGFR T790M's HGVS nomenclature is recorded as NP_005219.2:p.Thr790Met[11].
  • EGFR T790M's HGVS nomenclature is recorded as NC_000007.13:g.55249071C>T[12].
  • EGFR T790M's positive therapeutic predictor for is recorded as rociletinib[13].
  • EGFR T790M's positive therapeutic predictor for is recorded as staurosporine[14].
  • EGFR T790M's positive therapeutic predictor for is recorded as osimertinib[15].
  • EGFR T790M's positive therapeutic predictor for is recorded as osimertinib[16].
  • EGFR T790M's positive therapeutic predictor for is recorded as osimertinib[17].
  • EGFR T790M's positive therapeutic predictor for is recorded as rociletinib[18].
  • EGFR T790M's positive therapeutic predictor for is recorded as osimertinib[19].
  • EGFR T790M's positive therapeutic predictor for is recorded as osimertinib[20].
  • EGFR T790M's positive therapeutic predictor for is recorded as osimertinib[21].
  • EGFR T790M's positive therapeutic predictor for is recorded as neratinib[22].
  • EGFR T790M's positive therapeutic predictor for is recorded as afatinib[23].
  • EGFR T790M's positive therapeutic predictor for is recorded as canertinib[24].
  • EGFR T790M's positive therapeutic predictor for is recorded as pemetrexed / erlotinib combination therapy[25].
  • EGFR T790M's positive therapeutic predictor for is recorded as osimertinib[26].
  • EGFR T790M's positive therapeutic predictor for is recorded as rociletinib[27].

Why It Matters

EGFR T790M draws 10 Wikipedia views per month (missense_mutation category, ranking #1 of 1).[2] It has Wikipedia articles in 6 language editions, a strong signal of global cultural recognition.[28] It is known by 3 alternative names across languages and contexts.[29]

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [3] . CIViC database. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  2. [4] . CIViC database. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  3. [5] . CIViC database. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  4. [6] . CIViC database. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  5. [7] . wikidata.org.
  6. [8] . CIViC database. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  7. [9] . CIViC database. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  8. [10] . CIViC database. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  9. [11] . CIViC database. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  10. [12] . CIViC database. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  11. [13] . Rociletinib in EGFR-mutated non-small-cell lung cancer. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  12. [14] . A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  13. [15] . AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  14. [16] . AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  15. [17] . Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  16. [18] . Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  17. [19] . Osimertinib: First Global Approval. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  18. [20] . Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  19. [21] . EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  20. [22] . Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  21. [23] . BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  22. [24] . BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  23. [25] . Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  24. [26] . In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.
  25. [27] . In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Retrieved . civic.genome.wustl.edu. Provenance: wikidata.org.

Class ancestry

  1. [1] . Wikidata. wikidata.org.

Aggregate / graph-position facts

  1. [2] . Wikimedia Foundation. dumps.wikimedia.org.
  2. [28] . Wikidata sitelinks. wikidata.org.
  3. [29] . Wikidata aliases. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). EGFR T790M. Retrieved May 3, 2026, from https://4ort.xyz/entity/egfr-t790m
MLA “EGFR T790M.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/egfr-t790m.
BibTeX @misc{4ortxyz_egfr-t790m_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{EGFR T790M}}, year = {2026}, url = {https://4ort.xyz/entity/egfr-t790m}, note = {Accessed: 2026-05-03}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): EGFR T790M — https://4ort.xyz/entity/egfr-t790m (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/egfr-t790m · Last refreshed: